HCQ 1-4 days from diagnosis was the only protective factor against prolonged viral shedding found, OR 0.111, p=0.001. 57.1% viral clearance with 1-4 days delay vs. 22.9% for 5+ days delayed treatment. Authors report that early administration of HCQ significantly ameliorates inflammatory cytokine secretion and that COVID-19 patients should be administrated HCQ as soon as possible. 42 patients with HCQ 1-4 days from diagnosis, 48 with HCQ 5+ days from diagnosis.
|
risk of prolonged viral shedding, early vs. late HCQ, 64.9% lower, RR 0.35, p = 0.001, treatment 42, control 48, odds ratio converted to relative risk.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Hong et al., 16 Jul 2020, retrospective, South Korea, peer-reviewed, 7 authors, dosage not specified.
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication
Kyung Soo Hong, Jong Geol Jang, Jian Hur, Jong Ho Lee, PhD Hong Nam Kim, PhD Wonhwa Lee, June Hong Ahn
Infection & Chemotherapy, doi:10.3947/ic.2020.52.3.396
There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 -0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.
References
Ards Definition, Force, Ranieri, Rubenfeld, Thompson et al., Acute respiratory distress syndrome: the Berlin Definition, JAMA
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Engl J Med
Hong, Lee, Kim, Huh, Lee et al., Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea, Ann Lab Med,
doi:10.3343/alm.2020.40.5.351Mehta, Mcauley, Brown, Sanchez, Tattersall et al., HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet,
doi:10.1016/S0140-6736(20)30628-0Singer, Deutschman, Seymour, Shankar-Hari, Annane et al., The third international consensus definitions for sepsis and septic shock (Sepsis-3), JAMA
Smith, Prytherch, Meredith, Schmidt, Featherstone, The ability of the National Early Warning Score (NEWS) to discriminate patients at risk of early cardiac arrest, unanticipated intensive care unit admission, and death, Resuscitation,
doi:10.1016/j.resuscitation.2012.12.016Xu, Chen, Yuan, Yi, Ding et al., Factors associated with prolonged viral RNA shedding in patients with COVID-19, Clin Infect Dis
Zhou, She, Wang, Ma, The duration of viral shedding of discharged patients with severe COVID-19, Clin Infect Dis
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet,
doi:10.1016/S0140-6736(20)30566-3
